LDL and APOB Insights
Dan discusses the complexities of LDL receptor modulating therapies and their effects on LDL cholesterol and APOB levels. He emphasizes the importance of recognizing discordance between these metrics, suggesting that clinicians should prioritize APOB to better manage residual risks associated with elevated levels. The conversation highlights a potential gap in research regarding treatment strategies for APOB, aiming to mitigate lipid-related risks.In this clip
From this podcast
The Proof with Simon Hill
Why you should test ApoB | Dan Soffer, Md
Related Questions